People

Christian Angermayer is an entrepreneur and investor as well as the founder of Apeiron Investment Group, his family office and asset management business. Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has a deep experience and a proven track record of more than 20 years.

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion.

Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data.

Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion. Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data. Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

Aaron is a seasoned investor and operator of life science companies. He has provided expert counsel on numerous types of capital market issuances, emerging markets debt, covered bonds, high yield and restructurings. He has lead investor relations experience across several portfolios.

Greg Weaver has over 25 years of corporate strategic financial leadership as a career Chief Financial Officer (CFO) and board member in the biotech/medtech industry, guiding fundraising, capital markets, investor relations, financial reporting, and business operations planning. Greg Weaver currently serves as the CFO of BioIntelliSense, a US privately-held medtech company. Greg Weaver has served as a public biotech board member continuously since 2005, including as audit and compensation committee chairman, currently with Atossa Therapeutics, and formerly with Noxxon/TME Pharma N.V. (Berlin), Egalet Pharma, Celsion Therapeutics, and Oryzon (Barcelona).

Greg Weaver holds a B.S. in Accounting from Trinity University (Texas), an MBA from Boston College, and a US CPA certification. Greg Weaver has served in the US Air Force. He also serves on the board of the not-for-profit HarborPath, focused on serving patients suffering from AIDS and opioid addiction.

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Caleb has over 20 years of international finance experience across multiple sectors and geographies. He has worked in CFO roles as well as investment banking and over the course of his career has executed ~$30 billion of equity and debt financings spanning numerous industries and markets (US, Europe, and Asia).

Gabor is a seasoned biotech executive whose expertise spans drug discovery and venture capital financing. He has spent close to a decade developing immunotherapy programs and has executed a wide range of investments in both the private and public biotech sectors. In his current role, he focuses on strategic planning, fundraising efforts, and building strategic partnerships with leading pharmaceutical companies.

Karim brings more than 20 years of experience advising and counseling public and private companies in the biopharmaceutical industry. He has been successful in guiding and executing major transactions, and has experience establishing legal and compliance departments, making them a true business partner.

Aksana brings over 15 years of international experience in the life sciences and healthcare sectors, specializing in early-stage business development, company building, and venture investments. At Rejuveron, Aksana plays a pivotal role in overseeing the company’s investment strategy, guiding its strategic growth, and expanding a portfolio of innovative therapies designed to address age-related diseases. Her leadership is instrumental in shaping the future of Rejuveron’s mission to advance healthcare solutions for aging populations.

Caleb has over 20 years of international finance experience across multiple sectors and geographies. He has worked in CFO roles as well as investment banking and over the course of his career has executed ~$30 billion of equity and debt financings spanning numerous industries and markets (US, Europe, and Asia).

Gabor is a seasoned biotech executive whose expertise spans drug discovery and venture capital financing. He has spent close to a decade developing immunotherapy programs and has executed a wide range of investments in both the private and public biotech sectors. In his current role, he focuses on strategic planning, fundraising efforts, and building strategic partnerships with leading pharmaceutical companies.

Christian Angermayer is an entrepreneur and investor as well as the founder of Apeiron Investment Group, his family office and asset management business. Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has a deep experience and a proven track record of more than 20 years.

Aaron is a seasoned investor and operator of life science companies. He has provided expert counsel on numerous types of capital market issuances, emerging markets debt, covered bonds, high yield and restructurings. He has lead investor relations experience across several portfolios.

Aksana brings over 15 years of international experience in the life sciences and healthcare sectors, specializing in early-stage business development, company building, and venture investments. At Rejuveron, Aksana plays a pivotal role in overseeing the company’s investment strategy, guiding its strategic growth, and expanding a portfolio of innovative therapies designed to address age-related diseases. Her leadership is instrumental in shaping the future of Rejuveron’s mission to advance healthcare solutions for aging populations.

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion.

Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data.

Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion. Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data. Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

Greg Weaver has over 25 years of corporate strategic financial leadership as a career Chief Financial Officer (CFO) and board member in the biotech/medtech industry, guiding fundraising, capital markets, investor relations, financial reporting, and business operations planning. Greg Weaver currently serves as the CFO of BioIntelliSense, a US privately-held medtech company. Greg Weaver has served as a public biotech board member continuously since 2005, including as audit and compensation committee chairman, currently with Atossa Therapeutics, and formerly with Noxxon/TME Pharma N.V. (Berlin), Egalet Pharma, Celsion Therapeutics, and Oryzon (Barcelona).

Greg Weaver holds a B.S. in Accounting from Trinity University (Texas), an MBA from Boston College, and a US CPA certification. Greg Weaver has served in the US Air Force. He also serves on the board of the not-for-profit HarborPath, focused on serving patients suffering from AIDS and opioid addiction.